Written by Emanuele Arcà on Thursday 11th November 2021
Since our last whitepaper on digital therapeutics (DTx) in Europe, much has changed on the digital health and digital therapeutics landscape. Many European countries have established new assessment frameworks and evidence requirements for the evaluation of digital health products, including DTx. New medical device regulations define and categorize DTx, and the brand-new European pharmaceutical strategy prioritizes digital health infrastructure and its objectives.
In this whitepaper, we consider current assessment frameworks across the four biggest European countries: Germany, the United Kingdom, France, and Italy, and we look at current DTx reimbursement policies.
Please fill out this form to complete your request, and your download will begin immediately.